How big is Adaptive Biotechnologies Corp.?

As of Jun 18, Adaptive Biotechnologies Corp. has a market capitalization of $1.54 billion, with net sales of $189.53 million and a net loss of $141.90 million over the last four quarters. Shareholder's funds are valued at $202.71 million, and total assets amount to $539.38 million.

As of Jun 18, Adaptive Biotechnologies Corp. has a market capitalization of 1,540.44 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company's net sales for the latest four quarters amount to 189.53 million, while the net profit for the same period shows a loss of 141.90 million.<BR><BR>As of Dec 24, the reporting period for the balance sheet indicates that shareholder's funds are valued at 202.71 million, and total assets stand at 539.38 million.

What does Adaptive Biotechnologies Corp. do?

Adaptive Biotechnologies Corp. is a biotechnology company that develops diagnostics and treatments leveraging the adaptive immune system. As of March 2025, it reported net sales of $52 million and a net loss of $30 million, with a market cap of approximately $1.54 billion.

Overview: <BR>Adaptive Biotechnologies Corp. is a biotechnology company focused on utilizing the biology of the adaptive immune system to develop diagnostics and treatments for diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 52 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,540.44 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.26 <BR>Return on Equity: -70.23% <BR>Price to Book: 8.09<BR><BR>Contact Details: <BR>Address: 1551 Eastlake Ave E Ste 200, SEATTLE WA : 98102-7402 <BR>Tel: 1 206 6590067 <BR>Fax: 1 206 6590667 <BR>Website: https://www.adaptivebiotech.com

Should I buy, sell or hold Adaptive Biotechnologies Corp.?

Who are in the management team of Adaptive Biotechnologies Corp.?

As of March 2022, the management team of Adaptive Biotechnologies Corp. includes Chad Robins as Executive Chairman and CEO, with Peter Neupert as Lead Independent Director and independent directors Kevin Conroy, Eric Dobmeier, David Goel, and Michelle Griffin.

As of March 2022, the management team of Adaptive Biotechnologies Corp. includes Mr. Chad Robins, who serves as the Executive Chairman, Chief Executive Officer, and Co-Founder. Additionally, the board features Mr. Peter Neupert as the Lead Independent Director, along with independent directors Mr. Kevin Conroy, Mr. Eric Dobmeier, Mr. David Goel, and Ms. Michelle Griffin.

Is Adaptive Biotechnologies Corp. overvalued or undervalued?

As of November 12, 2019, Adaptive Biotechnologies Corp. is considered overvalued and rated as risky due to negative financial metrics, including a Price to Book Value of 8.05 and significant losses reflected in its ROCE and ROE, despite a strong recent stock performance.

As of 12 November 2019, the valuation grade for Adaptive Biotechnologies Corp. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears overvalued given its negative performance metrics, with a Price to Book Value of 8.05, an EV to EBIT of -10.97, and an EV to EBITDA of -12.74. In comparison, peers such as ADMA Biologics, Inc. have a fair valuation with a P/E of 18.56 and an EV to EBITDA of 23.86, while Kymera Therapeutics, Inc. is also rated risky with an EV to EBITDA of -8.04.<BR><BR>Despite strong recent returns, including a 198.70% increase over the past year compared to the S&P 500's 17.14%, the underlying financial ratios suggest that Adaptive Biotechnologies Corp. is not positioned favorably in the market. The significant losses reflected in its ROCE of -95.89% and ROE of -70.23% further support the conclusion that the company is currently overvalued.

Is Adaptive Biotechnologies Corp. technically bullish or bearish?

As of September 10, 2025, Adaptive Biotechnologies Corp. shows a bullish technical trend with strong momentum indicators, outperforming the S&P 500 significantly year-to-date and over the past year.

As of 10 September 2025, the technical trend for Adaptive Biotechnologies Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, and Bollinger Bands indicate bullish conditions as well. Daily moving averages also reflect a bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, while Dow Theory indicates a mildly bullish trend on both weekly and monthly timeframes. The On-Balance Volume is bullish for both timeframes.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 significantly across multiple periods, with a year-to-date return of 129.69% compared to the S&P 500's 12.22%, and a one-year return of 198.70% versus 17.14%. Overall, the current technical stance is bullish with strong momentum indicators supporting this view.